Women are twice as likely as men to get Alzheimer's disease. Despite advances in treatment, clinical trials have historically disregarded this epidemiological pattern due to recruitment bias. Data show disparate treatment effects in women, fueling calls for greater differentiation in diagnosis and drug discovery. Women present with depressive symptoms in the early stages, which are often overlooked or misdiagnosed by physicians, while men are more likely to be aggressive. With the same level of symptoms, women generally have more severe pathology, especially in tau protein aggregation. Female carriers of the APOE4 gene have a significantly higher risk of Alzheimer's disease than men with the same mutation. Studies need sufficient power to statistically analyse the differences between the sexes and publish these findings instead of hiding them in supplementary data. Hormonal changes at menopause affect disease progression, but characterizing their effect at the individual level is challenging[1].